




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : C12N 15/31, 15/55, 9/20</p>	<p>A1</p>	<p>(11) International Publication Number: WO 91/00908 (43) International Publication Date: 24 January 1991 (24.01.91)</p>
<p>(21) International Application Number: PCT/DK90/00170 (22) International Filing Date: 5 July 1990 (05.07.90) (30) Priority data: 3368/89 7 July 1989 (07.07.89) DK (71) Applicant (for all designated States except US): NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsvaerd (DK). (72) Inventor; and (75) Inventor/Applicant (for US only) : JØRGENSEN, Steen, Troels [DK/DK]; Prunusvej 5, DK-3450 Allerød (DK). (74) Common Representative: NOVO NORDISK A/S; Patent Department, Novo Allé, DK-2880 Bagsvaerd (DK).</p>		<p>(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent)*, DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent), US. Published With international search report.</p>

(54) Title: DNA ENCODING A LIPASE AND A LIPASE MODULATOR

(57) Abstract

A DNA sequence encoding a factor which acts *in trans* as a modulator of the production of a *Pseudomonas cepacia* lipase, or encoding an analogue of the lipase modulating factor, will, when present in a host cell which also contains a DNA sequence encoding said lipase, exert a beneficial effect on lipase production. The lipase modulating factor has this effect even when it or the lipase are expressed from heterologous expression signals or in heterologous cells.



* See back of page

DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Fasso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo			SN	Senegal
CH	Switzerland	KR	Republic of Korea	SU	Soviet Union
CM	Cameroon	LI	Liechtenstein	TD	Chad
DE	Germany, Federal Republic of	LK	Sri Lanka	TG	Togo
DK	Denmark	LU	Luxembourg	US	United States of America

DNA ENCODING A LIPASE AND A LIPASE MODULATOR

FIELD OF INVENTION

The present invention relates to a DNA sequence encoding a lipase, a DNA sequence the product of which affects the production of the lipase, expression vectors and host cells comprising these sequences, and a method of producing lipase by cultivating the host cells.

BACKGROUND OF THE INVENTION

Lipases are enzymes which catalyze the hydrolysis of ester bonds in triglycerides resulting in the formation of diglycerides, monoglycerides, glycerine and free fatty acids. Some lipases also catalyze other reactions involving ester bonds such as synthesis of ester bonds or transesterification reactions. Lipases are produced by a wide variety of different organisms. Microbial lipases in particular are of considerable practical utility for a variety of purposes where lipolysis of fats is desired, e.g. in the food industry and in detergents.

One particular lipase which has been found to be particularly advantageous for inclusion in a detergent for the removal of fatty stains or soiling from fabrics is a lipase produced by strains of Pseudomonas cepacia. In EP 214 761 (to Novo Industri A/S), this lipase is disclosed as a lipase which is active at a temperature below 60°C, which is important as most present-day fabrics are washed at temperatures below 60°C.

Another important Pseudomonas cepacia lipase for use as a detergent additive is the one disclosed in WO 89/01032 (to Novo Industri A/S) as a positionally non-specific lipase, i.e. one which is able to react with all three fatty acyl groups of a triglyceride.

In order to facilitate Pseudomonas cepacia lipase production, it may be advantageous to employ recombinant DNA techniques, for instance in order to optimize lipase expression by introducing a stronger promoter from which the DNA sequence encoding the enzyme is expressed or by introducing more efficient ribosome binding sites or signal peptide coding sequences, or in order to select a host organism for the production of the enzyme which is easier to cultivate (e.g. in terms of its being a standard production organism such as E.coli, B. subtilis or the like) or which results in higher lipase yields. As described below, such approaches will sometimes fail to yield the expected results, e.g. in cases where one or more genes in addition to the structural gene coding for the protein in question, play some part in the production of the gene product (examples of such genes are the Bacillus sac (Honjo, M., et al. (1987), Journal of Biotechnology, 6:191-204) and iep (Tanaka, T., Kawata, M. (1988), Journal of Bacteriology, 170:3593-3600) genes, and genes required for the production of Klebsiella pullulanase and E.coli hemolysin).

The cloning of a lipase gene from another Pseudomonas species, Pseudomonas fragi, is known from, e.g., S. Aoyama et al., FEBS Letters 242(1), December 1988, pp. 36-40, and W. Kugimiya et al., Biochem. Biophys. Res. Comm. 141(1), November 26, 1986, pp. 185-190. However, the lipase produced by P.fragi differs from that of P.cepacia in its amino acid sequence, and in these publications, there is no indication that one or more additional genes may be required in order to achieve a significant lipase production in a host organism.

EP 331 376 discloses a recombinant DNA encoding a Pseudomonas cepacia lipase as well as a protein participating in the production of the lipase. There is, however, no indication that the gene encoding this protein may also be functional in a heterologous host organism.

SUMMARY OF THE INVENTION

The present inventor has isolated and cloned a gene encoding a Pseudomonas cepacia lipase and identified a gene the expression of which is important to achieve production of the lipase in significant yields.

Accordingly, in a first aspect, the present invention relates to a DNA construct which comprises a DNA sequence encoding a factor which acts in trans as a modulator of the production of a Pseudomonas cepacia lipase, or encoding a functional analogue of the P. cepacia lipase modulating factor, the P. cepacia lipase modulating factor or functional analogue thereof being capable of modulating lipase production when the P. cepacia lipase is expressed using expression signals which are heterologous to Pseudomonas and/or when the P. cepacia lipase is expressed in a heterologous host cell.

In the course of the research leading to the present invention, it was surprisingly found that a region downstream of the DNA sequence coding for the lipase (as present on the chromosome of P. cepacia) has a pronounced beneficial effect on the production of the lipase. It was experimentally established (among other things, by inserting this region on a another plasmid than that carrying the DNA sequence encoding the lipase) that the region does not merely provide a site on the DNA sequence (such as a promoter, terminator, enhancer, or the like) which is required for lipase expression, but that the region includes a gene encoding a factor which is able to affect the production of the lipase even when the DNA sequences coding for the two products are not located on the same vector. The lipase modulating factor may be an RNA molecule or a polypeptide, but is most likely a polypeptide (cf. Example 3 below).

In the following, the DNA sequence encoding the lipase modulating factor will usually be referred to as the "lim" gene,

while the modulating factor will usually be referred to as the "Lim" factor.

It has surprisingly been found that expression of the lim gene exerts a beneficial effect on lipase production even when the lipase is expressed using expression signals which are heterologous to those of Pseudomonas (e.g. a promoter, ribosome binding site and signal peptide-coding region from a Bacillus α -amylase gene) or when the host organism is not Pseudomonas. Therefore, the Lim factor does not act on the initiation of either transcription or translation. However, the precise function of the Lim factor has yet to be elucidated.

The term "functional analogue" is understood to indicate a factor which has a similar lipase-production modulating function to that of the P.cepacia Lim factor and which is derived from another organism than P.cepacia, or which is a derivative of the P.cepacia Lim factor produced by modifying the DNA sequence in a manner resulting in addition, substitution, insertion or deletion of one or more amino acids in the native sequence. There is reason to believe, however, that such modifications of the native sequence should not be too extensive as the modulating function of the Lim factor may otherwise be lost. Apart from this, a functional analogue may be a homologous polypeptide (i.e. one encoded by DNA which hybridizes to the same probe as the DNA coding for the Lim factor under certain specified conditions [e.g. presoaking in 5xSSC and prehybridizing for 1h at -40°C in a solution of 20% formamide, 5xDenhardt's solution, 50mM sodium phosphate, pH 6.8, and 50 μg of denatured sonicated calf thymus DNA, followed by hybridization in the same solution supplemented with 100 μM ATP for 18h at -40°C]), or which is reactive with antibodies raised or directed against the Lim factor. When the term "Lim factor" is used in the following description, this is intended implicitly to include such functional analogues as well as the native P.cepacia lipase modulating factor.

DETAILED DISCLOSURE OF THE INVENTION

The DNA construct of the invention comprising the DNA sequence encoding the Lim factor may be of genomic or cDNA origin, for instance obtained by preparing a genomic or cDNA library of P.cepacia and screening for DNA sequences coding for all or part of the Lim factor by hybridization using synthetic oligonucleotide probes in accordance with standard techniques (cf. Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, 1982).

10 The DNA sequence encoding the Lim factor may be any one obtained from a lipase-producing P.cepacia strain. Examples of such strains are the ones deposited in the Deutsche Sammlung von Mikroorganismen in connection with the invention disclosed in EP 214 761, with the deposit numbers DSM 3333-3337
15 and DSM 3401, as well as the strain deposited in the Deutsche Sammlung von Mikroorganismen in connection with the invention disclosed in WO 89/01032, with the deposit number DSM 3959. It is, however, envisaged that a DNA sequence equivalent to the lim gene may also be derived from another lipase-producing
20 ducing organism. Such a gene may be screened for by hybridization using probes that hybridize to DNA encoding the Lim factor as described above or selected by the reactivity of its gene product with the same antibodies as the Lim factor or identified by screening for the ability to confer lipase
25 production to strains containing the lipase gene but not the lim gene.

The DNA construct of the invention encoding the Lim factor may also be prepared synthetically by established standard methods, e.g. the phosphoramidite method described by S.L.
30 Beaucage and M.H. Caruthers, Tetrahedron Letters 22, 1981, pp. 1859-1869, or the method described by Matthes et al., EMBO Journal 3, 1984, pp. 801-805. According to the phosphoramidite method, oligonucleotides are synthesized, e.g. in an

automatic DNA synthesizer, purified, ligated, and cloned in an appropriate vector.

Finally, the DNA construct may be of mixed synthetic and genomic, mixed synthetic and cDNA or mixed genomic and cDNA 5 origin prepared by ligating fragments of synthetic, genomic or cDNA origin (as appropriate), the fragments corresponding to various parts of the entire DNA construct, in accordance with standard techniques.

Preferred DNA constructs encoding the Lim factor are those 10 comprising a DNA sequence derived from the chromosome of P.cepacia, in particular those wherein the DNA sequence is located on the P. cepacia chromosome downstream of the sequence encoding a ~33 kD lipase. A particularly preferred DNA construct encoding the Lim factor is one which has the DNA 15 sequence shown in Fig. 1 A-C appended hereto or a modification thereof encoding a functional analogue of the P. cepacia Lim factor as defined above.

Examples of suitable modifications of the DNA sequence are nucleotide substitutions which do not give rise to another 20 sequence of the Lim factor, but which may correspond to the codon usage of the host organism into which the DNA construct is introduced or nucleotide substitutions which do give rise to a different sequence and therefore, possibly, a different structure without, however, impairing the properties of 25 either the lipase or the Lim factor. Other examples of possible modifications are insertion of one or more nucleotides into the sequence, addition of one or more nucleotides at either end of the sequence and deletion of one or more nucleotides at either end of or within the sequence.

30 For some purposes, it may be convenient to provide a DNA sequence encoding a Pseudomonas cepacia lipase on the same DNA construct as the DNA sequence encoding the Lim factor. Thus, the present invention further relates to a DNA construct

which comprises a first DNA sequence encoding a P. cepacia lipase or a derivative thereof and a second DNA sequence encoding the P. cepacia lipase modulating factor.

In the present context, the term "derivative" is intended to indicate a protein with lipolytic activity which is derived from the native lipase by suitably modifying the DNA sequence coding for the native lipase, resulting in the addition of one or more amino acids to either or both the C- and N-terminal end of the the native protein, substitution of one or more amino acids at one or a number of different sites in the native amino acid sequence, deletion of one or more amino acids at either or both ends of the native protein or at one or more sites in the amino acid sequence, or insertion of one or more amino acids at one or more sites in the native amino acid sequence. Such modifications of DNA coding for native proteins are well known and widely practised in the art.

Preferred DNA constructs encoding the P. cepacia lipase are those comprising a DNA sequence derived from P. cepacia, DSM 3959, encoding a lipase of ~33 kD which in nature is present on the chromosome of P. cepacia. A particularly preferred DNA construct encoding the lipase is one wherein the DNA sequence encoding the lipase is the one shown in Fig. 2 A-C appended hereto or a modification thereof encoding a derivative of the P. cepacia lipase as defined above.

In one embodiment of the DNA construct of the invention, the lipase DNA sequence may be located upstream of the sequence encoding the Lim factor, and in another embodiment, the DNA sequence encoding the lipase may be located downstream of the sequence encoding the Lim factor. In either case, the DNA sequences may be located relative to each other in such a way that they are transcribed from the same promoter under conditions permitting expression of the lipase and Lim factor when the DNA construct is present in a host cell. In a particular embodiment, the first DNA sequence encoding the lipase and/or

the second DNA sequence encoding the Lim factor may further comprise expression signals (e.g. a promoter, ribosome binding site and/or signal peptide-coding sequence) heterologous to those of Pseudomonas.

5 In a further aspect, the present invention relates to a replicable expression vector which carries an inserted DNA sequence encoding the Lim factor or a functional analogue thereof, as described above.

In a still further embodiment, the invention relates to a
10 replicable expression vector which carries a first inserted DNA sequence encoding the P. cepacia lipase or a derivative thereof (as described above) and a second DNA sequence encoding the Lim factor (as described above). In this case, the first and second DNA sequences may be expressed from the same
15 promoter although this need not be required. When the first and second DNA sequences are expressed from the same promoter, the lipase-encoding sequence may be located downstream or upstream of the Lim-encoding sequence without adversely affecting the modulation of lipase production effected by the
20 Lim factor.

Alternatively, the DNA sequences encoding the lipase and the Lim-polypeptide, respectively, may each be expressed from a separate promoter, even while carried on the same vector.

In a particular embodiment, the first DNA sequence encoding
25 the lipase and/or the second DNA sequence encoding the Lim factor may further comprise expression signals (e.g. a promoter, ribosome binding site and/or signal peptide-coding sequence) heterologous to those of Pseudomonas.

The replicable expression vector carrying a DNA sequence en-
30 coding the lipase and/or Lim factor may be any vector which is capable of replicating autonomously in a given host organism, typically a plasmid or bacteriophage. In the vector,

the DNA sequence encoding the lipase and/or Lim factor should be operably connected to a suitable promoter sequence. The promoter may be any DNA sequence which shows transcriptional activity in the host cell and may be derived from genes encoding proteins either homologous or heterologous to the host organism, e.g. a promoter which is heterologous to Pseudomonas. The promoter is preferably derived from a gene encoding a protein homologous to the host organism. Examples of suitable promoters are lac of E.coli, dagA of Streptomyces coelicolor and amyL of Bacillus licheniformis.

The replicable expression vector of the invention further comprises a DNA sequence enabling the vector to replicate in the host cell. Examples of such sequences are the origins of replication of plasmids pUC19, pACYC177, pUB110 and pIJ702.

- 15 The vector may also comprise a selectable marker, e.g. a gene whose product confers antibiotic resistance, such as ampicillin, kanamycin, chloramphenicol or tetracyclin resistance, or the dal genes from B.subtilis or B.licheniformis.
- 20 The procedures used to ligate the DNA sequences coding for the lipase and/or the Lim factor and the promoter, respectively, and to insert them into suitable vectors containing the information necessary for replication in the host cell, are well known to persons skilled in the art (cf., for instance, Sambrook et al., op.cit.). It will be understood that the vector may be constructed either by first preparing a DNA construct containing the entire DNA sequence coding for the lipase and for the Lim factor and subsequently inserting this construct into a suitable expression vector, or by preparing separate DNA constructs comprising DNA sequences encoding the lipase or the Lim factor, respectively, or by sequentially inserting DNA fragments containing genetic information for the individual elements (such as the lipase or Lim factor) followed by ligation after each step. It should further be understood that, in this connection, the DNA sequence en-

coding the lipase may be of genomic origin, while the sequence encoding the Lim factor may be prepared synthetically or vice versa, as described above.

In a still further aspect, the present invention relates to a host cell which contains either two separate DNA constructs comprising a DNA sequence encoding the P. cepacia lipase and a DNA sequence encoding the Lim factor as defined above, respectively, or a DNA construct comprising both DNA sequences on the same fragment; in either case, the DNA constructs may be integrated in the host chromosome which may be an advantage as the DNA sequences are more likely to be stably maintained in the cell. Integration of the DNA constructs into the host chromosome may be performed according to conventional methods, e.g. by homologous recombination. The two DNA sequences may be integrated in the host chromosome in such a way that they are each expressed from a separate promoter. In a particular embodiment, the DNA sequence encoding the lipase and/or the DNA sequence encoding the Lim factor may further comprise expression signals (e.g. a promoter, ribosome binding site and/or signal peptide-coding sequence) heterologous to those of Pseudomonas.

Alternatively, the host cell may be transformed with a replicable expression vector which contains both DNA sequences, or with two vectors containing the DNA sequence encoding the lipase and the DNA sequence encoding the Lim factor, respectively.

As a further alternative, the DNA sequence encoding the lipase may be integrated in the host chromosome, and the DNA sequence encoding the Lim factor may be carried on a replicable expression vector (as described above), or vice versa.

The host cell used in the process of the invention may be any suitable bacterium, yeast or filamentous fungus which, on cultivation, produces large amounts of the P. cepacia lipase.

Examples of suitable bacteria may be grampositive bacteria such as Bacillus subtilis, Bacillus licheniformis, Bacillus lentus, Bacillus brevis, Bacillus stearothermophilus, Bacillus alkalophilus, Bacillus amyloliquefaciens, Bacillus coagulans, Bacillus circulans, or Streptomyces lividans or Streptomyces murinus, or gramnegative bacteria such as E.coli. The transformation of the bacteria may for instance be effected by protoplast transformation or by using competent cells in a manner known per se.

10 The yeast organism may favourably be selected from a species of Saccharomyces, e.g. Saccharomyces cerevisiae. The filamentous fungus may advantageously belong to a species of Aspergillus, e.g. Aspergillus oryzae or Aspergillus niger. Fungal cells may be transformed by a process involving protoplast
15 formation and transformation of the protoplasts followed by regeneration of the cell wall in a manner known per se. The use of Aspergillus as a host organism is described in, e.g., EP 238 023.

In a yet further aspect, the present invention relates to a
20 method of producing the P. cepacia lipase or a derivative thereof, which method comprises cultivating a host cell as described above under conditions conducive to the production of the lipase or analogue thereof (including conditions ensuring the expression of the Lim factor), and recovering the
25 lipase or analogue from the cells and/or culture medium.

The medium used to cultivate the cells may be any conventional medium suitable for growing bacteria. The lipase may be recovered from the medium by conventional procedures including separating the cells from the medium by centrifugation or
30 filtration, if necessary after disruption of the cells, precipitating the proteinaceous components of the supernatant or filtrate by means of a salt, e.g. ammonium sulphate, followed by purification by a variety of chromatographic procedures,

e.g. ion exchange chromatography, affinity chromatography, or the like.

The invention is further illustrated by the following examples which are not in any way intended to limit the scope of the invention, with reference to the appended drawings, wherein

Fig. 1 A-C shows the DNA sequence of the P. cepacia lim gene, the derived amino acid sequence being shown below in the conventional three-letter code,

10 Fig. 2 A-C shows the DNA sequence encoding the ~33kD P. cepacia lipase, the derived amino acid sequence being shown below in the conventional three-letter code,

Fig. 3 schematically shows the construction of plasmid pSJ518,

15 Fig. 4 schematically shows the construction of plasmid pSJ910,

Fig. 5 schematically shows the construction of plasmid pSJ485,

Fig. 6 A-B schematically shows the construction of plasmids
20 pSJ622 and pSJ624,

Fig. 7 schematically shows the construction of plasmid pSJ424,

Fig. 8 schematically shows the construction of plasmids pSJ494 and 909,

25 Fig. 9 schematically shows the construction of plasmid pSJ729,

Fig. 10 schematically shows the construction of plasmid pSJ416,

Fig. 11 schematically shows the construction of plasmid pSJ600,

5 Fig. 12 schematically shows the construction of plasmid pSJ671, and

Fig. 13 A-B schematically shows the construction of plasmid pSJ669.

MATERIALS AND METHODS

10 Bacterial strains:

E. coli HW1 is a lacI^q, z M15 derivative of strain 803 described in Wood, 1966.

E. coli NM539 is described in Frischauf et al., 1983, and was obtained from Promega.

15 Pseudomonas cepacia SB10, DSM 3959, is described in WO 89/01032.

Bacillus subtilis DN1885 is a amyE, amyR2, Spo⁺, Pro⁺ derivative of B. subtilis 168.

Bacillus licheniformis ATCC 9789.

20 Streptomyces lividans TK24 is described in Hopwood et al., 1983.

Phages:

Lambda EMBL4 is described in Frischauf et al., 1983. It was obtained from Promega.

Plasmids:

5 pUC18 and pUC19 are described in Yanisch-Perron et al., 1985.

pACYC177 is described in Chang and Cohen 1978.

pIJ702 is described in Katz et al., 1983.

pIJ4642 is an E.coli cloning vector allowing positive selection for inserts. It resembles pIJ666 (Kieser and Melton, 10 Gene 65, 1988, pp. 83-91) but has more useful sites for cloning. It was obtained from T. Kieser.

pDN1528 is a derivative of the B. subtilis plasmid pUB110 (Gryczan et al., 1978), carrying a 2.3 kb HindIII - SphI fragment containing the alpha-amylase gene from B. licheniformis 15 strain DN52, an amylase-overproducing derivative of ATCC9789 produced by conventional mutagenesis procedures.

pPL1131 is a pUB110-derived plasmid containing the amylase promoter and signal peptide-coding region of pDN1528 followed by a synthetic linker.

20 pIJ2002 is a pUC18 derivative containing the daqA (agarase) gene of S. coelicolor A3(2). It is described in Buttner et al., 1987, and was obtained from M. Bibb.

General Methods:

Standard DNA manipulations were performed essentially as described in Maniatis et al., 1982. 25

Restriction enzymes, T4 DNA ligase, T4 polynucleotide kinase, DNA Polymerase I (Klenow Fragment), and Exonuclease III were obtained from New England Biolabs and used as recommended by the supplier. Nuclease S1 and the restriction enzyme HindII
5 were obtained from Boehringer Mannheim and used as recommended by the supplier.

Chicken egg white lysozyme was obtained from Sigma.

Preparation of plasmids from all strains was conducted by the method described by Kieser (1984).

10 Lambda DNA was packaged in vitro using the Packagene extract from Promega.

DNA sequencing was performed by the dideoxy chain termination method (Sanger et al., 1977) using ³⁵SdATP (DuPont NEN NEG034H, >1000 Ci/mmol) as the radioactive label and using
15 denatured plasmid DNAs as templates. Sequencing was either carried out as described in Hattori and Sakaki, 1986, using the Klenow fragment, or by means of Sequenase™ as described in the booklet from the supplier (United States Biochemical Corporation). Primers were either the M13 sequencing and re-
20 verse sequencing primers from New England Biolabs or oligonucleotides (17-21 mers) complementary to regions of the cloned Pseudomonas DNA prepared by the present inventor.

Transformation of E. coli:

25 Cells of E. coli were made competent and transformed as described by Mandel and Higa, 1970.

Transformation of B. subtilis:

Competent cells were prepared and transformed as described by Yasbin et al., 1975.

Transformation of B. licheniformis:

30 Plasmids were introduced into B. licheniformis by polyethylene glycol-mediated protoplast transformation as described by Akamatzu (1984).

Transformation of S. lividans:

Transformation and other procedures for Streptomyces were as described in Hopwood et al., 1985.

Oligonucleotide synthesis:

- 5 Synthesis was performed on an automatic DNA synthesizer using the phosphoramidite method described by Beaucage and Caruthers, Tetrahedron Letters 22, 1981, pp. 1859-1869. Crude oligonucleotides were purified by polyacrylamide gel electrophoresis.

10 Preparation of phage DNA:

Phage lambda DNA was prepared from small-scale liquid cultures as described in Maniatis et al., 1982.

Exo III deletions:

- 15 Unidirectional deletions were made using Exonuclease III as described by Henikoff, 1984.

Lipase analysis

Lipase was measured by a pH-stat method using tributyrine as substrate. 1 LU (Lipase Unit) is the amount of enzyme which
20 liberates 1 umole titratable butyric acid per minute under the following conditions:

	Temperature	30.0 °C
	pH	7.0
	Emulsifier	Gum Arabic, 1 g/l
25	Substrate	Tributyrine, 50 ml/l

Media:

	TY: Trypticase	20	g/l
	Yeast extract	5	g/l
	FeCl ₂ .4H ₂ O	6	mg/l
30	MnCl ₂ .4H ₂ O	1	mg/l
	MgSO ₄ .7H ₂ O	15	mg/l
	pH	7.3	

	BPX:	Potato starch	100 g/l
		Barley flour	50 g/l
		BAN 5000 SKB	0.1g/l
		Sodium caseinate	10 g/l
5		Soy Bean Meal	20 g/l
		Na ₂ HPO ₄ , 12 H ₂ O	9 g/l
		Pluronic	0.1g/l

	LB agar:	Bacto-tryptone	10 g/l
		Bacto yeast extract	5 g/l
10		NaCl	10 g/l
		Bacto agar	15 g/l
		Adjusted to pH 7.5 with NaOH	

LB agar with tributyrine:

15 To 350 ml of melted LB agar is added 3.5 ml tributyrine and 0.35 g Gum Arabic, the mixture is emulsified using an Ultra Turrax emulsifier and then autoclaved.

Nile Blue indicator plates:

The bottom layer consisted of 15 ml LB agar.
 20 The top layer contained a mixture of 3 ml soft agar (LB with 0.6 % agar), 300 µl olive oil emulsion and 20 µl of a 5% Nile Blue solution (made up in water and sterile filtered).

Olive Oil emulsion:

	Olive oil	10 ml
25	Gum Arabic	1 g
	Deionised water	90 ml

mixed using an Ultra Turrax emulsifier.

Buffers:

TE buffer: 10 mM Tris, pH 8, 1 mM EDTA, pH 8.

Phage buffer: 0.01 M NaCl
0.01 M MgCl₂
0.01 M Tris.HCl, pH 7.0

Ligation buffer: 0.066 M Tris.HCl pH 7.5, 0.01 M MgCl₂, 25
5 μg/ml gelatine, 0.001 M ATP, 0.01 M DTT.

EXAMPLE 1

Cloning of the Pseudomonas cepacia lipase geneA) Preparation of chromosomal DNA from Pseudomonas cepacia SB10.

10 A pellet of frozen cells from a 3 ml TY culture was resuspended in 1 ml TE buffer containing 1 mg/ml lysozyme. 0.1 ml EDTA (0.5 M, pH 8.0) was added and the mixture was incubated at 37 °C for 15 min. with gentle shaking. 5 μl 20% SDS was added, and the solution was repeatedly extracted with phenol
15 (300 μl portions) until no interface was present. The supernatant was then extracted once with CHCl₃ (300 μl). To 900 μl supernatant, 90 μl 3 M Na-acetate and 500 μl isopropanol were added. After 5-10 minutes, the precipitated DNA was recovered on a plastic inoculating loop, washed in 70 and 96 % EtOH and
20 resuspended in 500 μl TE. The solution of chromosomal DNA (chrDNA) was kept at -20 °C.

B) Partial cutting and fractionation of chrDNA from P. cepacia.

80 μg chrDNA from P.cepacia SB10 (prepared as described in
25 section A above) was digested with 5 units Sau3A at 37 °C for 5 minutes in 400 μl of the buffer recommended by the supplier, and heated at 70 °C for 10 min, and the total sample was then loaded on a preparative agarose gel. After elec-

trophoresis, gel segments containing DNA fragments of 9-23 kb were cut out. The chromosomal DNA fragments were recovered in the liquid formed after freezing/thawing the gel segments, extracted twice with phenol, once with CHCl_3 , ethanol precipitated and dissolved in TE buffer.

C) Construction of a *P. cepacia* DNA library in phage lambda.

2 μg lambda EMBL4 DNA was digested completely with restriction enzymes BamHI and SallI, extracted twice with phenol, once with CHCl_3 , ethanol precipitated and resuspended in 10 μl TE. The suspension was mixed with 2.5 μg size-fractionated chrDNA (in 50 μl TE), ethanol precipitated, resuspended in 10 μl ligation buffer, 100 units of T4 DNA ligase were added and ligation was carried out for 2 h at room temperature followed by 16 hours at 4°C. The ligated DNA was then packaged into 15 lambda phage particles using the Packagene™ extract from Promega, diluted in 500 μl phage buffer and 50 μl CHCl_3 were added. This was used for making an amplified phage stock as follows: Packaged phage particles were mixed with an equal volume of a fresh overnight culture of *E. coli* NM539 grown in 20 TY + 0.4 % maltose + 20 mM MgSO_4 , allowed to adsorb for 20 minutes at 37°C and plated on fresh LB plates in 4 ml soft LB agar (0.6 %) containing 20 mM MgSO_4 . After incubation at 37°C for 16 hours, the partially lysed top layer containing about 2500 plaques was scraped into a 40 ml centrifuge tube containing 25 5 ml phage buffer, and phage eluted for 2 hours. The supernatant after centrifugation at 5000 rpm for 5 min. in a Sorvall SS34 rotor was kept as an amplified stock and used for screening.

D) Isolation of a recombinant lambda phage carrying a lipase 30 gene.

About 200000 phages from the amplified library were adsorbed to NM539 and plated on 20 LB plates in soft agar containing 1 % glycerol tributyrate emulsion, resulting in total lysis on

each plate. 170 clear plaques (hydrolysing the tributyrine) were identified in the turbid tributyrine emulsion, and a number reisolated. 35 plaques were streaked on Nile Blue indicator plates and 10 of these gave a positive reaction, i.e. a strong blue colouring. Phage DNA was isolated from three of these phages, which were found to be identical, based on restriction enzyme digests.

E) Subcloning into pUC19

1 μg of the phage DNA prepared in section D above was partially cut with SalI, mixed with 0.3 μg SalI digested pUC19 DNA, ligated, transformed into competent E. coli HW1 and plated on LB plates containing 200 $\mu\text{g}/\text{ml}$ ampicillin. These plates were replicated onto LB plates with 200 $\mu\text{g}/\text{ml}$ ampicillin and 1 % glycerol tributyrate emulsion, and colonies surrounded by clear halos were isolated. One of these, SJ150, was shown to harbour a plasmid, designated pSJ150, of approximately 6 kb, including the lipase-coding gene and the lipase modulating (lim) gene.

F) DNA sequencing

The sequence of most of the cloned DNA contained on pSJ150 was determined by the dideoxy chain terminating method directly on double-stranded templates, as described in Materials and Methods above. The sequences of both strands were determined, using a combination of subcloning of restriction fragments, deletions from either end of the cloned DNA using Exonuclease III, and synthetic oligonucleotide primers. This allowed identification of the lipase coding sequence shown in Fig. 2A-C, and the lipase modulator (lim) coding sequence shown in Fig. 1A-C. On pSJ150, the sequence TCG separates the lipase modulator start codon (ATG) from the lipase stop codon (TAA).

EXAMPLE 2

Expression of the Pseudomonas cepacia lipase**A. Expression of the unmodified lipase in E.coli**(1) lip without lim

5 Plasmid pSJ518 was constructed by subcloning the 1.5 kb HindIII-ClaI fragment containing the lipase (lip) gene from pSJ150 into pUC19, as shown in Fig. 3. Strain SJ518 (E. coli HW1 containing pSJ518) does not produce any lipase as seen on plates containing 1 % glycerol tributyrates (i.e. no halos
10 surround the colonies).

(2) lip + lim on the same plasmid

On pSJ150, the lipase is expressed from its own as well as from the pUC19 lac promoter. The plasmid pSJ910, containing the same fragment of cloned DNA but in the reverse orientation with respect to the lac promoter, was constructed as
15 outlined in Fig. 4 and introduced into E. coli HW1 to form strain SJ910. When plated on plates containing 1 % glycerol tributyrates, SJ910 colonies were surrounded by smaller halos than colonies of SJ150. This indicates the presence of a pro-
20 moter, active in E. coli, for the lip and lim genes.

The region between the lip and lim genes can be changed without negatively affecting lipase expression. pSJ150 contains a unique ClaI site one basepair after the lipase stop codon. Plasmid pSJ485 was constructed by insertion of an 8 basepair
25 BglIII linker (New England Biolabs) into this ClaI site which had been filled-in using the large fragment of DNA polymerase I (Klenow fragment) and dNTP's, thus giving a 10 basepair insertion (Fig. 5). Strain SJ485 (E. coli HW1 containing pSJ485) produced the same amounts of lipase as SJ150.

(3) lip and lim on separate plasmids

The lim gene was excised on a 1.2 kb SphI fragment from pSJ150 and inserted into the SphI site of pUC19. This resulted in plasmids pSJ377, with the lac promoter reading correctly into the lim gene, and pSJ378, with the lac promoter reading backwards into the lim gene. From pSJ377 and pSJ378, the 1.2 kb insert + the lac promoter could be excised as a 1.5 kb PvuII fragment. This was inserted into the HindII site of pACYC177 to give pSJ622 (insert from pSJ377) and pSJ624 (insert from pSJ378). The construction of pSJ622 and pSJ624 is outlined in Fig. 6.

Plasmids pSJ622 and pSJ624 were introduced into competent SJ518 (the strain containing pSJ518 with the lipase gene alone), selecting for ampicillin and kanamycin resistance, and the transformants were replicated onto plates containing glycerol tributyrates. Large halos were formed around transformants containing pSJ622, but none around transformants containing pSJ624, indicating lipase production from the former but not from the latter.

20 B. Expression of a modified lipase gene in E.coli(1) lip without lim

pSJ494 is an expression plasmid for the P.cepacia lipase in Bacillus. It has the promoter, ribosome binding site and signal peptide coding region from the B. licheniformis alpha-amylase gene fused in-frame to DNA coding for the mature lipase, but does not contain the lim gene. The construction of pSJ494 is outlined in Figs. 7 and 8. The sequence of the fusion region is as follows:

ATG AAA CAA CAA AAA CGG CTT TAC GCC CGA TTG CTG ACG CTG
 30 Met Lys Gln Gln Lys Arg Leu Tyr Ala Arg Leu Leu Thr Leu
 alpha-amylase signal peptide

PstI

TTA TTT GCG CTC ATC TTC TTG CTG CCT CAT TCT GCA GCA GCG GCC
 Leu Phe Ala Leu Ile Phe Leu Leu Pro His Ser Ala Ala Ala Ala

MluI

5 GCA GCT GGC TAC GCG GCG ACG CGT TAC CCG ATC - -
 Ala Ala Gly Tyr Ala Ala Thr Arg Tyr Pro Ile - -
 | mature lipase sequence

In order to introduce this alpha-amylase/lipase fusion gene into E. coli, plasmid pSJ909 was constructed (Fig. 8). Strain 10 SJ909 (E. coli HW1 containing pSJ909) does not produce any halos on plates containing glycerol tributyrates.

(2) lip and lim on separate plasmids

Strain SJ909 was made competent and transformed with either pSJ377 (constructed as shown in Fig. 6) or pSJ729, which was 15 derived from pSJ377 by deleting about 600 basepairs from the 5' terminal of the lim gene (Fig. 9). When the double transformants were streaked on plates containing glycerol tributyrates, those containing pSJ377 (the lim⁺ plasmid) formed clear halos around the colonies, indicating lipase produc- 20 tion, whereas those containing pSJ729 (lim⁻) did not form any halos.

C. Expression of a modified lipase gene in B. subtilis(1) lip without lim

Plasmids pSJ493 and pSJ495 are identical to pSJ494, described 25 in section B.1), carrying the amylase-lipase fusion but no lim gene. They were introduced into B. subtilis strain DN1885 and transformants were grown for 4 days at 37 °C in shake flasks containing BPX growth medium, with the addition of oleyl alcohol to 30 g/l and chloramphenicol to 12 µg/ml.

lipase activity in the culture broth was measured by the LU-titrimetric method (described in Materials and Methods) and was 1-2 LU/ml. This is not above the background level found for strain DN1885, which varies between 0-5 LU/ml.

5 (2) lip and lim on the same plasmid

Plasmid pSJ416 contains the same amylase-lipase fusion as pSJ493-495, but the lipase gene is followed immediately downstream by the lim gene in exactly the same way as on pSJ150 (the construction of pSJ416 is outlined in Fig. 10).

10 When this plasmid was introduced into B. subtilis DN1885 and transformants grown in shake flasks as described above, yields reached 40 LU/ml in 4 days.

D. Expression of a modified lipase gene in B.licheniformis

(1) lip without lim

15 Plasmid pSJ488 contains the same amylase-lipase fusion as pSJ493, but on the Bacillus vector pPL1131 conferring kanamycin resistance to its host strain (Fig. 11). This plasmid was introduced into B. licheniformis strain ATCC 9789 by protoplast transformation, and the transformants were streaked
20 on plates containing glycerol tributyrates. The halos formed around the transformants were very small, of the same size as those formed around the untransformed strain.

(2) lip and lim on the same plasmid

Plasmid pSJ600 contains the same amylase-lipase fusion as
25 pSJ488, but the lipase gene is followed immediately downstream by the lim gene in exactly the same way as on pSJ150 (the construction of pSJ600 is outlined in Fig. 11). When this plasmid was introduced into B. licheniformis ATCC 9789 by protoplast transformation, and the transformants were

streaked on plates containing glycerol tributyrates, pronounced halos were formed around the colonies indicating lipase production.

E. Expression of a modified lipase gene in S.lividans

5 (1) lip without lim-expression

Plasmid pSJ604 was constructed by isolating a 880 bp HindIII-AvaII fragment from plasmid pIJ2002, carrying the dagA promoters and part of the signal peptide-encoding sequence (cf. Fig. 2 in Buttner et al., 1987). To the fragment were added 10 two complementary, phosphorylated and annealed oligonucleotides of the following sequence:

AvaII

MluI XhoI

GTCCCGCACCCGCCGCTCATGCCGCAGCTGGCTACGCGGCGACGCGTC

GGCGTGGGCGGCGAGTACGGCGTCGACCGATGCGCCGCTGCGCAGAGCT

15 This mixture was ligated to pUC19 which had previously been digested with HindIII and SalI to give plasmid pSJ604.

Plasmid pSJ671 is an E. coli-S. lividans shuttle plasmid carrying an in-frame fusion between the promoter, ribosome binding site and signal peptide coding region of the S. coelicolor 20 agarase gene (dagA, Buttner et al., 1987) and the DNA coding for the mature lipase. The lim gene is present on the plasmid, but in such a position that it is not transcribed by any known promoters. The construction of pSJ671 is outlined in Fig. 12, and the sequence of the fusion region is 25 as follows:

GTG GTC AAC CGA CGT GAT CTC ATC AAG TGG AGT GCC GTC GCA
Met Val Asn Arg Arg Asp Leu Ile Lys Trp Ser Ala Val Ala
agarase signal peptide

AvaII

CTC GGA GCG GGT GCG GGG CTC GCG GGT CCC GCA CCC GCC GCT CAT
 Leu Gly Ala Gly Ala Gly Leu Ala Gly Pro Ala Pro Ala Ala His

5

MluI

GCC GCA GCT GGC TAC GCG GCG ACG CGT TAC CCG ATC -
 Ala Ala Ala Gly Tyr Ala Ala Thr Arg Tyr Pro Ile

| mature lipA sequence

10 When pSJ671 was introduced into S. lividans TK24 by protoplast transformation and the resulting transformants were streaked on plates containing glycerol tributyrates, very small halos were formed around the colonies, indicating little or no lipase production.

15 (2) lip and lim on the same plasmid

pSJ669 is similar to pSJ671 with the exception that pSJ669 contains the lim gene immediately downstream from the lipase gene in exactly the same way as on pSJ150 (the construction of pSJ669 is outlined in Fig. 13).

20 When pSJ669 was introduced as described above into S. lividans TK24 and transformants were streaked on plates with glycerol tributyrates, very large halos were formed around the colonies, compared to those around pSJ671.

F. Effect of a modified lim gene

25 pSJ377, shown in Fig. 6, contains the lim gene expressed from a lacZ promoter. This plasmid was digested with ClaI, and deletions around the ClaI site were generated using ExoIII. One such deletion plasmid is pSJ721, in which 15 base pairs were deleted, which created a fusion protein derived from the

(Wang et al., 1990) after creating blunt ends with the Klenow fragment of DNA polymerase I. Recombinant plasmids were obtained with the lim gene inserted in either of the two possible orientations. pCBE3 and pCBE4 both contain the lim gene in the correct orientation for transcription from the temperature-inducible lambda pR and pL promoters on pJW2, whereas pCBE2 contain the lim gene in the opposite orientation. The plasmids were introduced into E. coli JA221 (Clarke and Carbon, 1978), and transcription from the pL and pR promoters was induced by increasing the temperature of the cultures to 42 °C. Proteins produced upon induction were identified by polyacrylamide gel electrophoresis of cells harvested from the induced cultures. This allowed identification of a protein of an apparent molecular weight of 34000 which was found in induced cultures of transformants carrying pCBE3 and pCBE4, but not in the induced culture of the transformant carrying pCBE2, or in uninduced cultures.

REFERENCES.

Akamatzu, T., Sekiguchi, J. (1984). An improved method of protoplast regeneration for Bacillus species and its application to protoplast fusion and transformation. Agric. Biol. Chem. 48, 651-655.

Buttner, M. J., Fearnley, I. M., Bibb, M. J. (1987). The agarase gene (dagA) of Streptomyces coelicolor A3(2): Nucleotide sequence and transcriptional analysis. Mol. Gen. Genet. 209, 101-109.

Chang, A. C. Y., Cohen, S. N. (1978). Construction and Amplification of Amplifiable Multicopy DNA Cloning Vehicles Derived from the p15A Cryptic Miniplasmid. J. Bacteriol. 134, 1141-1156.

Clarke, L. and Carben, J. (1978). J.Mol.Biol. 120, pp. 517-534.

- Frischauf, A.-M., Lehrach, H., Poutstka, A., Murray, N. (1983). Lambda Replacement Vectors Carrying Polylinker Sequences. *J. Mol. Biol.* 170, 827-842.
- Hattori, M., Sakaki, Y. (1986). Dideoxy Sequencing Method
5 Using Denatured Plasmid Templates. *Anal. Biochem.* 152, 232-238.
- Henikoff, S. (1984). Unidirectional digestion with exonuclease III creates targeted breakpoints for DNA sequencing. *Gene* 28, 351-359.
- 10 Hopwood, D. A., Bibb, M. J., Chater, K. F., Kieser, T., Bruton, C. J., Kieser, H. M., Lydiate, D. J., Smith, C. P., Ward, J. M., Schrepf, H. (1985). Genetic manipulation of *Streptomyces*. A laboratory manual. The John Innes Foundation, Norwich.
- 15 Hopwood, D. A., Kieser, T., Wright, H. M., Bibb, M. J. (1983). Plasmids, Recombination and Chromosome Mapping in *Streptomyces lividans* 66. *J. Gen. Microbiol.* 129, 2257-2269.
- Katz, E., Thompson, C. J., Hopwood, D. A. (1983). Cloning and expression the tyrosinase gene from *Streptomyces antibioticus*
20 in *Streptomyces lividans*. *J. Gen. Microbiol.* 129, 2703-2714.
- Kieser, T. (1984). Factors affecting the isolation of CCC DNA from *Streptomyces lividans* and *Escherichia coli*. *Plasmid* 12, 19-36.
- Mandel, M., Higa, A. (1970). Calcium-dependent bacteriophage
25 DNA infection. *J. Mol. Biol.* 53, 159-162.
- Maniatis, T., Fritsch, E. F., Sambrook, J. (1982). *Molecular Cloning: A Laboratory Manual*. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.

Yanisch-Perron, C., Vieira, J., Messing, J. (1985). Improved M13 phage cloning vectors and host strains: Nucleotide sequences of the M13mp18 and pUC19 vectors. *Gene*, 33, 103-119.

Yasbin, R. E., Wilson, G. A., Young, F. E. (1975) Transformation and transfection of lysogenic strains of Bacillus subtilis: evidence for selective induction of prophage in competent cells. *J. Bacteriol.* 121, 296-304.

Wang, H. et al. (1990). An efficient temperature-inducible vector incorporating the T7 gene 10 translation initiation 10 region. *Nucl. Acids Res.* 18, p. 1070.

Wood, W. B. (1966). Host specificity of DNA produced by Escherichia coli: Bacterial mutations affecting the restriction and modification of DNA. *J. Mol. Biol.* 16, 118-133.

CLAIMS

1. A DNA construct which comprises a DNA sequence encoding a factor which acts in trans as a modulator of the production of a Pseudomonas cepacia lipase, or encoding a functional analogue of the P. cepacia lipase modulating factor, the P. cepacia lipase modulating factor or functional analogue thereof being capable of modulating lipase production when the P. cepacia lipase is expressed using expression signals which are heterologous to Pseudomonas and/or when the P. cepacia lipase is expressed in a heterologous host cell.
2. A DNA construct according to claim 1, wherein the DNA sequence is derived from the chromosome of P. cepacia.
3. A DNA construct according to claim 2, wherein the DNA sequence is located on the P. cepacia chromosome downstream of a DNA sequence encoding a ~33 kD lipase.
4. A DNA construct according to claim 1, wherein the DNA sequence is the one shown in the appended Fig. 1 A-C or a modification thereof encoding a functional analogue of the P. cepacia lipase modulating factor.
5. A DNA construct which comprises a first DNA sequence encoding a P. cepacia lipase or a derivative thereof, and a second DNA sequence encoding a P. cepacia lipase modulating factor as defined in any of claims 1-4.
6. A DNA construct according to claim 5, wherein the first DNA sequence encodes a ~33 kD lipase.
7. A DNA construct according to claim 5, wherein the DNA sequence is the one shown in the appended Fig. 2 A-C or a modification thereof encoding a derivative of the P. cepacia lipase.

8. A DNA construct according to claim 5, wherein the DNA sequence encoding the P. cepacia lipase is located upstream of the DNA sequence encoding P. cepacia lipase modulating factor.
- 5 9. A DNA construct according to claim 5, wherein the DNA sequence encoding the P. cepacia lipase is located downstream of the DNA sequence encoding the P. cepacia lipase modulating factor.
10. A DNA construct according to any of claims 5-9, wherein
10 the first and/or second DNA sequence further comprises expression signals heterologous to those of Pseudomonas.
11. A replicable expression vector which carries an inserted DNA sequence encoding a factor which acts in trans as a modulator of the production of a P. cepacia lipase, or encoding a
15 functional analogue of the P. cepacia lipase modulating factor, the P. cepacia lipase modulating factor or functional analogue thereof being capable of modulating lipase production when the P. cepacia lipase is expressed using expression signals which are heterologous to Pseudomonas and/or when the
20 P. cepacia lipase is expressed in a heterologous host cell.
12. A vector according to claim 11, wherein the DNA sequence is as defined in any of claims 2-4.
13. A replicable expression vector which carries a first inserted DNA sequence encoding a P. cepacia lipase or a derivative thereof, and a second inserted DNA sequence encoding a
25 P. cepacia lipase modulating factor as defined in any of claims 1-4.
14. A vector according to claim 13, wherein the first DNA sequence encodes a ~33 kD lipase.

15. A vector according to claim 14, wherein the DNA sequence is the one shown in the appended Fig. 2 A-B or a modification thereof encoding a derivative of the P. cepacia lipase.
16. A vector according to claim 13, wherein the first and
5 second DNA sequence are expressed from the same promoter.
17. A vector according to claim 16, wherein the first DNA sequence encoding the P. cepacia lipase is located upstream of the second DNA sequence encoding the P. cepacia lipase modulating factor.
- 10 18. A vector according to claim 16, wherein the first DNA sequence encoding the P. cepacia lipase is located downstream of the second DNA sequence encoding the P. cepacia lipase modulating factor.
- 15 19. A vector according to claim 13, wherein the first DNA sequence encoding the P. cepacia lipase and the second DNA sequence encoding the P. cepacia lipase modulating factor are each expressed from a separate promoter.
- 20 20. A vector according to any of claims 13-19, wherein the first and/or second DNA sequence further comprises expression signals heterologous to those of Pseudomonas.
21. A host cell containing a first DNA construct comprising a DNA sequence encoding a P. cepacia lipase or a derivative thereof, and a second DNA construct according to any of claims 1-4.
- 25 22. A host cell according to claim 21, wherein the first DNA construct encodes a ~33 kD lipase.
23. A host cell according to claim 22, wherein the DNA sequence of the DNA construct is the one shown in the appended

Fig. 2 A-B or a modification thereof encoding a derivative of the P. cepacia lipase.

24. A host cell according to any of claims 21-23, wherein the first and/or second DNA construct further comprises expression signals heterologous to those of Pseudomonas.

25. A host cell containing a DNA construct according to any of claims 5-10.

26. A host cell according to claim 21, which is transformed with a replicable expression vector carrying the first DNA construct, and with a replicable expression vector according to claim 11.

27. A host cell according to claim 26, wherein the DNA sequence encoding the P. cepacia lipase further comprises expression signals heterologous to those of Pseudomonas.

28. A host cell according to claim 21 which is transformed with a replicable expression vector according to any of claims 13-20.

29. A host cell according to claim 21, which carries the first DNA construct integrated in its chromosome, and which contains a replicable expression vector according to claim 11.

30. A host cell according to claim 21, which carries the second DNA construct integrated in its chromosome, and which contains a replicable expression vector containing the first DNA construct.

31. A host cell according to claim 21, which carries the first and second DNA construct integrated in its chromosome in such a way that the DNA sequence coding for the P. cepacia

lipase and the DNA sequence coding for the lipase modulating factor are each expressed from a separate promoter.

32. A host cell according to any of claims 21-31 which is a bacterium, yeast or filamentous fungus.

5 33. A host cell according to claim 32 which is a grampositive bacterium.

34. A host cell according to claim 33, wherein the grampositive bacterium is selected from the group consisting of Bacillus subtilis, Bacillus licheniformis, Bacillus lentus,
10 Bacillus brevis, Bacillus stearothermophilus, Bacillus alkalophilus, Bacillus amyloliquefaciens, Bacillus coagulans, Bacillus circulans, or Streptomyces lividans or Streptomyces murinus.

35. A host cell according to claim 32 which is a gramnegative
15 tive bacterium, e.g. Escherichia coli.

36. A method of producing a P. cepacia lipase or a derivative thereof, which method comprises cultivating a host cell according to any of claims 21-35 under conditions conducive to the production of the lipase or analogue, and recovering the
20 lipase or analogue from the culture medium.

1/19

			10			20			30			40		
ATG	ACG	GCA	CGA	GGA	GGA	CGC	GCG	CCG	CTG	GCG	CGC	CGC	GCC	GTG
MET	Thr	Ala	Arg	Gly	Gly	Arg	Ala	Pro	Leu	Ala	Arg	Arg	Ala	Val
	50			60				70			80			90
GTC	TAT	GGT	GCC	GTG	GGG	CTG	GCG	GCG	ATT	GCC	GGC	GTG	GCG	ATG
Val	Tyr	Gly	Ala	Val	Gly	Leu	Ala	Ala	Ile	Ala	Gly	Val	Ala	MET
			100			110			120			130		
TGG	AGC	GGC	GCG	GGC	CGG	CAT	GGC	GGG	ACG	GCC	GCA	TCC	GCC	GAG
Trp	Ser	Gly	Ala	Gly	Arg	His	Gly	Gly	Thr	Gly	Ala	Ser	Gly	Glu
	140			150				160			170			180
CCG	CCG	GAT	GCG	TCG	GCG	GCA	CGC	GGA	CCG	GCT	GCC	GCA	CCG	CCG
Pro	Pro	Asp	Ala	Ser	Ala	Ala	Arg	Gly	Pro	Ala	Ala	Ala	Pro	Pro
			190			200			210			220		
CAG	GCC	GCC	GTG	CCG	GCA	AGC	ACG	AGC	CTG	CCG	CCG	TCG	CTC	GCC
Gln	Ala	Ala	Val	Pro	Ala	Ser	Thr	Ser	Leu	Pro	Pro	Ser	Leu	Ala
	230			240				250			260			270
GGC	TCC	AGC	GCG	CCC	CGC	TTG	CCG	CTC	GAT	GCC	GGC	GGC	CAT	CTC
Gly	Ser	Ser	Ala	Pro	Arg	Leu	Pro	Leu	Asp	Ala	Gly	Gly	His	Leu
			280			290			300			310		
GCG	AAG	GCG	CGC	GCG	GTG	CGG	GAT	TTC	TTC	GAC	TAC	TGC	CTG	ACC
Ala	Lys	Ala	Arg	Ala	Val	Arg	Asp	Phe	Phe	Asp	Tyr	Cys	Leu	Thr
	320			330				340			350			360
GCG	CAG	AGC	GAC	CTG	AGT	GCG	GCC	GGG	CTC	GAT	GCG	TTC	GTC	ATG
Ala	Gln	Ser	Asp	Leu	Ser	Ala	Ala	Gly	Leu	Asp	Ala	Phe	Val	MET
			370			380			390			400		
CGC	GAG	ATT	GCC	GCA	CAG	CTC	GAC	GGG	ACC	GTT	GCG	CAG	GCC	GAG
Arg	Glu	Ile	Ala	Ala	Gln	Leu	Asp	Gly	Thr	Val	Ala	Gln	Ala	Glu
	410			420				430			440			450
GCG	CTC	GAC	GTG	TGG	CAC	CGG	TAT	CGC	GCG	TAT	CTC	GAC	GCA	CTC
Ala	Leu	Asp	Val	Trp	His	Arg	Tyr	Arg	Ala	Tyr	Leu	Asp	Ala	Leu
			460			470			480			490		
GCG	AAA	TTG	CGC	GAT	GCC	GGC	GCG	GTC	GAC	AAG	TCG	GAC	CTG	GGT
Ala	Lys	Leu	Arg	Asp	Ala	Gly	Ala	Val	Asp	Lys	Ser	Asp	Leu	Gly

Fig. 1a

2/19

500		510		520		530		540							
GCA	TTG	CAG	CTC	GCG	CTC	GAC	CAG	CGC	GCG	TCG	ATC	GCG	TAC	CGG	
Ala	Leu	Gln	Leu	Ala	Leu	Asp	Gln	Arg	Ala	Ser	Ile	Ala	Tyr	Arg	
		550		560		570		580							
	TGG	CTC	GGC	GAC	TGG	AGC	CAG	CCG	TTC	TTC	GGT	GCG	GAG	CAA	TGG
	Trp	Leu	Gly	Asp	Trp	Ser	Gln	Pro	Phe	Phe	Gly	Ala	Glu	Gln	Trp
		590		600		610		620		630					
	CGG	CAG	CGC	TAC	GAC	CTC	GCG	CGG	CTG	AAG	ATC	GCG	CAG	GAC	CCC
	Arg	Gln	Arg	Tyr	Asp	Leu	Ala	Arg	Leu	Lys	Ile	Ala	Gln	Asp	Pro
		640		650		660		670							
	GCG	CTG	ACG	GAT	GCG	CAG	AAG	GCC	GAA	CGG	CTC	GCG	GCG	CTC	GAA
	Ala	Leu	Thr	Asp	Ala	Gln	Lys	Ala	Glu	Arg	Leu	Ala	Ala	Leu	Glu
		680		690		700		710		720					
	CAG	CAG	ATG	CCG	GCC	GAC	GAA	CGC	GCC	GCG	CAG	CAG	CGC	GTC	GAC
	Gln	Gln	MET	Pro	Ala	Asp	Glu	Arg	Ala	Ala	Gln	Gln	Arg	Val	Asp
		730		740		750		760							
	CGG	CAG	CGC	GCG	GCG	ATC	GAC	CAG	ATC	GCG	CAA	TTG	CAG	AAG	AGC
	Arg	Gln	Arg	Ala	Ala	Ile	Asp	Gln	Ile	Ala	Gln	Leu	Gln	Lys	Ser
		770		780		790		800		810					
	GGG	GCG	ACG	CCC	GAT	GCG	ATG	CGC	GCA	CAA	CTG	ACG	CAG	ACG	CTC
	Gly	Ala	Thr	Pro	Asp	Ala	MET	Arg	Ala	Gln	Leu	Thr	Gln	Thr	Leu
		820		830		840		850							
	GGC	CCC	GAA	GCG	GCC	GCG	CGC	GTC	GCG	CAG	ATG	CAG	CAG	GAC	GAC
	Gly	Pro	Glu	Ala	Ala	Ala	Arg	Val	Ala	Gln	MET	Gln	Gln	Asp	Asp
		860		870		880		890		900					
	GCA	TCG	TGG	CAG	AGG	CGC	TAC	GCG	GAC	TAC	GCG	GCG	CAG	CGT	GCG
	Ala	Ser	Trp	Gln	Arg	Arg	Tyr	Ala	Asp	Tyr	Ala	Ala	Gln	Arg	Ala
		910		920		930		940							
	CAG	ATC	GAG	TCG	GCC	GGC	CTG	TCG	CCG	CAG	GAT	CGC	GAC	GCG	CAG
	Gln	Ile	Glu	Ser	Ala	Gly	Leu	Ser	Pro	Gln	Asp	Arg	Asp	Ala	Gln
		950		960		970		980		990					
	ATC	GCC	GCG	CTG	CGG	CAG	CGC	GTG	TTT	ACG	AAG	CCC	GGC	GAA	GCC
	Ile	Ala	Ala	Leu	Arg	Gln	Arg	Val	Phe	Thr	Lys	Pro	Gly	Glu	Ala

Fig. 1 b

3/19

1000 1010 1020 1030
GTG CGC GCG GCA TCG CTC GAT CGC GGG GCG GGC AGC GCG CGG
Val Arg Ala Ala Ser Leu Asp Arg Gly Ala Gly Ser Ala Arg

Fig. 1c

4/19

			10			20			30			40		
ATG	GCC	AGG	ACG	ATG	CGT	TCC	AGG	GTG	GTG	GCA	GGG	GCA	GTG	GCA
MET	Ala	Arg	Thr	MET	Arg	Ser	Arg	Val	Val	Ala	Gly	Ala	Val	Ala
	50			60			70			80			90	
TGC	GCG	ATG	AGC	ATC	GCG	CCG	TTC	GCG	GGG	ACG	ACC	GCG	GTG	ATG
Cys	Ala	MET	Ser	Ile	Ala	Pro	Phe	Ala	Gly	Thr	Thr	Ala	Val	MET
		100			110			120			130			
ACG	CTC	GCG	ACG	ACG	CAC	GCG	GCA	ATG	GCG	GCC	ACC	GCG	CCC	GCC
Thr	Leu	Ala	Thr	Thr	His	Ala	Ala	MET	Ala	Ala	Thr	Ala	Pro	Ala
	140			150			160			170			180	
GCT	GGC	TAC	GCG	GCG	ACG	CGT	TAC	CCG	ATC	ATC	CTC	GTG	CAC	GGG
Ala	Gly	Tyr	Ala	Ala	Thr	Arg	Tyr	Pro	Ile	Ile	Leu	Val	His	Gly
		190			200			210			220			
CTC	TCG	GGT	ACC	GAC	AAG	TAC	GCC	GGC	GTG	CTC	GAG	TAT	TGG	TAC
Leu	Ser	Gly	Thr	Asp	Lys	Tyr	Ala	Gly	Val	Leu	Glu	Tyr	Trp	Tyr
	230			240			250			260			270	
GGC	ATC	CAG	GAG	GAC	CTG	CAA	CAG	AAC	GGT	GCG	ACC	GTC	TAC	GTC
Gly	Ile	Gln	Glu	Asp	Leu	Gln	Gln	Asn	Gly	Ala	Thr	Val	Tyr	Val
		280			290			300			310			
GCG	AAC	CTG	TCG	GGT	TTC	CAG	AGC	GAC	GAC	GGC	CCG	AAC	GGG	CGC
Ala	Asn	Leu	Ser	Gly	Phe	Gln	Ser	Asp	Asp	Gly	Pro	Asn	Gly	Arg
	320			330			340			350			360	
GGC	GAA	CAG	TTG	CTC	GCT	TAC	GTG	AAG	ACG	GTG	CTC	GCG	GCG	ACG
Gly	Glu	Gln	Leu	Leu	Ala	Tyr	Val	Lys	Thr	Val	Leu	Ala	Ala	Thr
		370			380			390			400			
GGG	GCG	ACC	AAG	GTC	AAT	CTC	GTC	GGT	CAC	AGC	CAG	GGC	GGC	CTC
Gly	Ala	Thr	Lys	Val	Asn	Leu	Val	Gly	His	Ser	Gln	Gly	Gly	Leu
	410			420			430			440			450	
TCG	TCG	CGC	TAT	GTT	GCT	GCC	GTC	GCG	CCC	GAT	CTC	GTT	GCG	TCG
Ser	Ser	Arg	Tyr	Val	Ala	Ala	Val	Ala	Pro	Asp	Leu	Val	Ala	Ser
		460			470			480			490			
GTG	ACG	ACG	ATC	GGC	CCA	GCC	GAT	CGC	GGC	TCC	GAA	TTC	GCC	GAC
Val	Thr	Thr	Ile	Gly	Pro	Ala	Asp	Arg	Gly	Ser	Glu	Phe	Ala	Asp

Fig. 2 a

5/19

500		510		520		530		540						
TTC	GTG	CAG	GAC	GTG	CTC	GCG	TAC	GAT	CCG	ACC	GGG	CTT	TCG	TCA
Phe	Val	Gln	Asp	Val	Leu	Ala	Tyr	Asp	Pro	Thr	Gly	Leu	Ser	Ser
	550		560		570		580							
TCG	GTG	ATC	GCC	GCG	TTC	GTC	AAT	GTG	TTC	GGG	ATC	CTG	ACG	AGC
Ser	Val	Ile	Ala	Ala	Phe	Val	Asn	Val	Phe	Gly	Ile	Leu	Thr	Ser
	590		600		610		620		630					
AGC	AGC	CAC	AAC	ACC	AAC	CAG	GAC	GCG	CTC	GCC	GCA	CTG	CAG	ACC
Ser	Ser	His	Asn	Thr	Asn	Gln	Asp	Ala	Leu	Ala	Ala	Leu	Gln	Thr
	640		650		660		670							
CTG	ACC	ACC	GCA	CGG	GCC	GCC	ACG	TAC	AAC	CAG	AAC	TAT	CCG	AGC
Leu	Thr	Thr	Ala	Arg	Ala	Ala	Thr	Tyr	Asn	Gln	Asn	Tyr	Pro	Ser
	680		690		700		710		720					
GCG	GGC	CTG	GGT	GCG	CCG	GGC	AGT	TGC	CAG	ACC	GGT	GCG	CCG	ACC
Ala	Gly	Leu	Gly	Ala	Pro	Gly	Ser	Cys	Gln	Thr	Gly	Ala	Pro	Thr
	730		740		750		760							
GAA	ACC	GTC	GGC	GGC	AAC	ACG	CAC	CTG	CTG	TAT	TCG	TGG	GCC	GGC
Glu	Thr	Val	Gly	Gly	Asn	Thr	His	Leu	Leu	Tyr	Ser	Trp	Ala	Gly
	770		780		790		800		810					
ACG	GCG	ATC	CAG	CCG	ACG	CTC	TCC	GTG	TTC	GGC	GTC	ACG	GGC	GCG
Thr	Ala	Ile	Gln	Pro	Thr	Leu	Ser	Val	Phe	Gly	Val	Thr	Gly	Ala
	820		830		840		850							
ACG	GAC	ACG	AGC	ACC	CTT	CCG	CTC	GTC	GAT	CCG	GCG	AAC	GTG	CTC
Thr	Asp	Thr	Ser	Thr	Leu	Pro	Leu	Val	Asp	Pro	Ala	Asn	Val	Leu
	860		870		880		890		900					
GAC	CTG	TCG	ACG	CTC	GCG	CTG	TTC	GGC	ACC	GGC	ACG	GTG	ATG	ATC
Asp	Leu	Ser	Thr	Leu	Ala	Leu	Phe	Gly	Thr	Gly	Thr	Val	MET	Ile
	910		920		930		940							
AAC	CGC	GGC	TCC	GGG	CAG	AAC	GAC	GGG	CTC	GTG	TCG	AAG	TGC	AGT
Asn	Arg	Gly	Ser	Gly	Gln	Asn	Asp	Gly	Leu	Val	Ser	Lys	Cys	Ser
	950		960		970		980		990					
GCG	CTG	TAC	GGC	AAG	GTG	CTG	AGC	ACG	AGC	TAC	AAG	TGG	AAC	CAC
Ala	Leu	Tyr	Gly	Lys	Val	Leu	Ser	Thr	Ser	Tyr	Lys	Trp	Asn	His

Fig. 2 b

6/19

```

          1000          1010          1020          1030
CTC GAC GAG ATC AAC CAG CTG CTC GGC GTG CGC GGC GCG TAT GCG
Leu Asp Glu Ile Asn Gln Leu Leu Gly Val Arg Gly Ala Tyr Ala

    1040          1050          1060          1070          1080
GAA GAT CCC GTC GCG GTG ATC CGC ACG CAT GCG AAC CGG CTG AAG
Glu Asp Pro Val Ala Val Ile Arg Thr His Ala Asn Arg Leu Lys

          1090
CTG GCG GGC GTG
Leu Ala Gly Val
```

Fig. 2 c

7/19




Fig. 3

9/19




Fig. 5

10/19




Fig. 6a

11/19




Fig. 6b

12/19




Fig. 7




Fig. 8

16/19




Fig. 11

19/19




Fig. 13b

INTERNATIONAL SEARCH REPORT

International Application No PCT/DK 90/00170

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC5: C 12 N 15/31, 15/55, 9/20																	
II. FIELDS SEARCHED <div style="text-align: center; margin-top: 5px;">Minimum Documentation Searched⁷</div> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr> <td style="width: 20%; padding: 5px;">Classification System</td> <td style="padding: 5px;">Classification Symbols</td> </tr> <tr> <td style="padding: 5px;">IPC5</td> <td style="padding: 5px;">C 12 N</td> </tr> </table> <div style="text-align: center; margin-top: 5px;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in Fields Searched⁸</div> <p style="margin-top: 10px;">SE,DK,FI,NO classes as above</p>			Classification System	Classification Symbols	IPC5	C 12 N											
Classification System	Classification Symbols																
IPC5	C 12 N																
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹ <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <thead> <tr> <th style="width: 10%; padding: 5px;">Category *</th> <th style="width: 70%; padding: 5px;">Citation of Document,¹¹ with indication, where appropriate, of the relevant passages¹²</th> <th style="width: 20%; padding: 5px;">Relevant to Claim No.¹³</th> </tr> </thead> <tbody> <tr> <td style="padding: 5px;">P,X</td> <td style="padding: 5px;">EP, A2, 0331376 (AMANO PHARMACEUTICAL CO., LTD) 6 September 1989, see the whole document --</td> <td style="padding: 5px;">1-36</td> </tr> <tr> <td style="padding: 5px;">A</td> <td style="padding: 5px;">EP, A2, 0318775 (CHISSO CORPORATION) 7 June 1989, see the whole document --</td> <td style="padding: 5px;">1-36</td> </tr> <tr> <td style="padding: 5px;">A</td> <td style="padding: 5px;">WO, A1, 8901032 (NOVO INDUSTRI A/S) 9 February 1989, see the whole document --</td> <td style="padding: 5px;">1-36</td> </tr> <tr> <td style="padding: 5px;">A</td> <td style="padding: 5px;">EP, A2, 0214761 (NOVO INDUSTRI A/S) 18 March 1987, see the whole document -- -----</td> <td style="padding: 5px;">1-36</td> </tr> </tbody> </table>			Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	P,X	EP, A2, 0331376 (AMANO PHARMACEUTICAL CO., LTD) 6 September 1989, see the whole document --	1-36	A	EP, A2, 0318775 (CHISSO CORPORATION) 7 June 1989, see the whole document --	1-36	A	WO, A1, 8901032 (NOVO INDUSTRI A/S) 9 February 1989, see the whole document --	1-36	A	EP, A2, 0214761 (NOVO INDUSTRI A/S) 18 March 1987, see the whole document -- -----	1-36
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³															
P,X	EP, A2, 0331376 (AMANO PHARMACEUTICAL CO., LTD) 6 September 1989, see the whole document --	1-36															
A	EP, A2, 0318775 (CHISSO CORPORATION) 7 June 1989, see the whole document --	1-36															
A	WO, A1, 8901032 (NOVO INDUSTRI A/S) 9 February 1989, see the whole document --	1-36															
A	EP, A2, 0214761 (NOVO INDUSTRI A/S) 18 March 1987, see the whole document -- -----	1-36															
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none; vertical-align: top;"> <p>* Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </td> <td style="width: 50%; border: none; vertical-align: top;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </td> </tr> </table>			<p>* Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>													
<p>* Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>																
IV. CERTIFICATION <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr> <td style="width: 50%; padding: 5px;">Date of the Actual Completion of the International Search</td> <td style="width: 50%; padding: 5px;">Date of Mailing of this International Search Report</td> </tr> <tr> <td style="padding: 5px;">8th October 1990</td> <td style="padding: 5px; text-align: center;">1990 -10- 12</td> </tr> <tr> <td style="padding: 5px;">International Searching Authority</td> <td style="padding: 5px;">Signature of Authorized Officer</td> </tr> <tr> <td style="padding: 5px; text-align: center;">SWEDISH PATENT OFFICE</td> <td style="padding: 5px; text-align: center;"> Mikael G:son Bergstrand </td> </tr> </table>			Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	8th October 1990	1990 -10- 12	International Searching Authority	Signature of Authorized Officer	SWEDISH PATENT OFFICE	Mikael G:son Bergstrand							
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report																
8th October 1990	1990 -10- 12																
International Searching Authority	Signature of Authorized Officer																
SWEDISH PATENT OFFICE	Mikael G:son Bergstrand																

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.PCT/DK 90/00170**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the Swedish Patent Office EDP file on **90-08-28**.
The Swedish Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A2- 0331376	89-09-06	NONE	
EP-A2- 0318775	89-06-07	JP-A- 1291789 JP-A- 2039890	89-11-24 90-02-08
WO-A1- 8901032	89-02-09	EP-A- 0382738	90-08-22
EP-A2- 0214761	87-03-18	JP-A- 62034997 US-A- 4876024	87-02-14 89-10-24